scholarly journals Sodium–glucose Cotransporter 2 Inhibitors’ Rise to the Backbone of Heart Failure Management: A Clinical Review

2021 ◽  
Vol 15 (1) ◽  
pp. 42
Author(s):  
Namit Rohant ◽  
Jamie LW Kennedy ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Clinical Review ◽  
Heart Failure Management ◽  
Sodium Glucose Cotransporter

scholarly journals SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AS NEW STRATEGY OF CHRONIC HEART FAILURE MANAGEMENT

2020 ◽  
Vol 7 (3) ◽  
pp. 209-214
Author(s):  
Andrii S. Herashchenko ◽  
Sergiy V. Fedorov
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Clinical Practice ◽  
High Morbidity ◽  
Current Clinical Practice ◽  
Heart Failure Management ◽  
Common Cause ◽  
Sodium Glucose Cotransporter ◽  
New Strategy ◽  
Patients With Diabetes

Introduction: Heart failure (HF) affects over 26 million people worldwide and is associated with high morbidity and mortality. Diabetes mellitus (DM) is a common cause of HF in current clinical practice. In recent years, the prevalence of DM has increased considerably, with an estimated 439 million adults worldwide projected to be affected by the year 2030. The aim: To was evaluate of modern trials in patients with diabetes and heart failure treated by Sodium-glucose cotransporter-2 inhibitors. Materials and Methods: The database from PubMed for the last 10 years has been reviewed. Conclusion: SGLT2i, namely Empagliflozin, has good results in their recovery from patients with HFrEF, but the results of their use in patients with HFpEF are currently questionable and need further study.

652 Is heart rate lowering per se beneficial in chronic heart failure management and permanent cardiac pacing?

2007 ◽  
Vol 6 (1) ◽  
pp. 139-139
Author(s):  
D LOGEART ◽  
V CIOBOTARU ◽  
J GUEFFET ◽  
F POUSSET ◽  
F ROUZET ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Chronic Heart Failure ◽  
Cardiac Pacing ◽  
Heart Failure Management ◽  
Per Se

Natriuretic Peptides – Addressing the Dilemma of Heart Failure Management

2011 ◽  
Vol 7 (2) ◽  
pp. 104
Author(s):  
Kenneth McDonald ◽  
Ulf Dahlström ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Physical Examination ◽  
Natriuretic Peptides ◽  
Normal Values ◽  
Outpatient Setting ◽  
Heart Failure Management ◽  
Effective Screening ◽  
Specific Symptoms ◽  
Objective Marker

Heart failure (HF) is characterised by non-specific symptoms and unremarkable physical examination; therefore, the need exists for an available objective marker of HF status. Natriuretic peptides (NPs) are a marker that can aid the dilemmas in present-day HF management. More effective screening for clinical deterioration would include changes in brain natriuretic peptide (BNP) levels. Normal values for BNP, <50–100 pg/ml, have excellent negative predictive value (NPV) in excluding HF as a diagnosis. BNP values that are significantly elevated, e.g. >500 pg/ml, make the diagnosis of HF more likely. There are now established and emerging uses for NPs in managing HF in the community. These include the role of NPs at the time of possible new presentation of HF, its role in prognostication and, finally, the increasing interest in using NPs to guide therapy in the outpatient setting.

Urgent need to reorganize heart failure management

2005 ◽  
Vol 60 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Gilles W. DE KEULENAER ◽  
Dirk L. BRUTSAERT
Keyword(s):  
Heart Failure ◽  
Heart Failure Management

Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction

2019 ◽  
Vol 19 (20) ◽  
pp. 1818-1849 ◽  
Author(s):  
Ban Liu ◽  
Yuliang Wang ◽  
Yangyang Zhang ◽  
Biao Yan
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Renal Dysfunction ◽  
Sglt2 Inhibitors ◽  
Sodium Glucose Cotransporter ◽  
Glucose Reabsorption ◽  
Renal Glucose Reabsorption

: Type 2 diabetes mellitus is one of the most common forms of the disease worldwide. Hyperglycemia and insulin resistance play key roles in type 2 diabetes mellitus. Renal glucose reabsorption is an essential feature in glycaemic control. Kidneys filter 160 g of glucose daily in healthy subjects under euglycaemic conditions. The expanding epidemic of diabetes leads to a prevalence of diabetes-related cardiovascular disorders, in particular, heart failure and renal dysfunction. Cellular glucose uptake is a fundamental process for homeostasis, growth, and metabolism. In humans, three families of glucose transporters have been identified, including the glucose facilitators GLUTs, the sodium-glucose cotransporter SGLTs, and the recently identified SWEETs. Structures of the major isoforms of all three families were studied. Sodium-glucose cotransporter (SGLT2) provides most of the capacity for renal glucose reabsorption in the early proximal tubule. A number of cardiovascular outcome trials in patients with type 2 diabetes have been studied with SGLT2 inhibitors reducing cardiovascular morbidity and mortality. : The current review article summarises these aspects and discusses possible mechanisms with SGLT2 inhibitors in protecting heart failure and renal dysfunction in diabetic patients. Through glucosuria, SGLT2 inhibitors reduce body weight and body fat, and shift substrate utilisation from carbohydrates to lipids and, possibly, ketone bodies. These pleiotropic effects of SGLT2 inhibitors are likely to have contributed to the results of the EMPA-REG OUTCOME trial in which the SGLT2 inhibitor, empagliflozin, slowed down the progression of chronic kidney disease and reduced major adverse cardiovascular events in high-risk individuals with type 2 diabetes. This review discusses the role of SGLT2 in the physiology and pathophysiology of renal glucose reabsorption and outlines the unexpected logic of inhibiting SGLT2 in the diabetic kidney.

Quality still doesn't pay in heart failure management

2003 ◽  
Vol 9 (4) ◽  
pp. 263-265 ◽  
Author(s):  
David J. Whellan ◽  
Daniel B. Mark
Keyword(s):  
Heart Failure ◽  
Heart Failure Management

scholarly journals Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure

Heart ◽  
2021 ◽  
pp. heartjnl-2020-318658
Author(s):  
Kieran F Docherty ◽  
Mark C Petrie
Keyword(s):  
Heart Failure ◽  
Sodium Glucose Cotransporter
Sign in / Sign up

Export Citation Format

Share Document